Data as of 11:34am ET
| -0.16 / -3.84%|
Sorrento Therapeutics is engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics that address significant unmet medical needs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic and infectious diseases. Sorrento's clinical pipeline includes Cynviloq (paclitaxel in polymeric micelle formulation) which is entering a registrational bio-equivalent study versus albumin-bound paclitaxel (Abraxane, Celgene); and Resiniferatoxin (RTX), which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In addition, Sorrento has one of the industry's most diverse fully human antibody libraries (G-MAB) and novel toxins/proprietary conjugation chemistries allowing Sorrento to generate antibody-drug conjugates (ADCs). The Sorrento ADCs have well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to the development of a new of generation ADCs with improved stability and pharmacokinetics while reducing off-target effects. Sorrento Therapeutics was founded by Henry Ji, in 2006 and is headquartered in San Diego, CA.
|Henry H. Ji||President, Chief Executive Officer & Director|
|Richard Glenn Vincent||Chief Financial Officer, Secretary & EVP|
|Zhenwei Miao||Chief Technology Officer|
|Mike A. Royal||Executive VP-Clinical & Regulatory Affairs|
|Amar Singh||Chief Business Officer & Executive Vice President|